---
title: "Quest Diagnostics Jumps as Q4 Revenue Rises 7.1%, Lazard Gains 0.35% on AUM"
canonical_url: https://www.stockexpertai.com/journal/2026-02-10/quest-diagnostics-jumps-as-q4-revenue-rises-71-lazard-gains-035-on-aum
last_updated: 2026-02-10T12:07:31.776Z
section: "Earnings Watch"
author: "Taylor Brooks"
publisher: Stock Expert AI
tickers: DGX, LAZ, MCD, AZN, FERG
content_type: journal-article
---

# Quest Diagnostics Jumps as Q4 Revenue Rises 7.1%, Lazard Gains 0.35% on AUM

## The Take
- Focus on companies demonstrating revenue growth and strong financial guidance, but be aware that market reactions can be unpredictable.

_Earnings season brings key insights. Quest beats expectations, while investors eye McDonald's upcoming report._

Earnings season brings clarity—and volatility. Quest Diagnostics (DGX) is in the spotlight after releasing its fourth-quarter and full-year 2025 financial results. DGX reported a 7.1% increase in fourth-quarter revenues, reaching $2.81 billion, compared to 2024. The company's full-year revenue also saw an 11.8% increase from 2024, totaling $11.04 billion. Following the news, DGX saw a modest gain of 0.28%, trading at $191.25.

Lazard (LAZ) also reported its preliminary assets under management (AUM) as of January 31, 2026, totaling approximately $267.0 billion. This includes market appreciation of $7.6 billion and net inflows of $2.9 billion. LAZ shares reacted positively, increasing 0.35% to $57.00. These figures provide a snapshot of the current investment landscape, highlighting areas of growth and investor confidence.

Looking ahead, McDonald's (MCD) is set to release its fourth-quarter earnings on Wednesday morning. Analysts anticipate that the fast-food giant's stock could reach new highs following the results. However, today MCD saw a slight decline of -0.48%, trading at $325.60. Investors will be closely watching to see if McDonald's can meet these high expectations.

AstraZeneca (AZN) also reported its full-year results, showcasing a robust operational performance. However, AZN experienced a decline of -2.60%, trading at $188.01. The mixed reactions across these companies underscore the complexities of earnings season, where positive results don't always translate to immediate stock gains.

## Related Tickers
- [DGX](https://www.stockexpertai.com/stock/dgx)
- [LAZ](https://www.stockexpertai.com/stock/laz)
- [MCD](https://www.stockexpertai.com/stock/mcd)
- [AZN](https://www.stockexpertai.com/stock/azn)
- [FERG](https://www.stockexpertai.com/stock/ferg)

## Frequently Asked Questions

### What were Quest Diagnostics' Q4 earnings?
Quest Diagnostics (DGX) reported a 7.1% increase in Q4 revenue, reaching $2.81 billion. Full-year revenue also rose 11.8% to $11.04 billion. The stock saw a modest gain following the announcement.

### How did Lazard's AUM perform?
Lazard (LAZ) reported preliminary assets under management (AUM) of approximately $267.0 billion as of January 31, 2026, with market appreciation and net inflows contributing to the increase. The stock rose 0.35%.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._